Key result
Wearable mHealth devices support early screening and real-time monitoring for acute cardiovascular disease during pandemics.
Because of the rapid and serious nature of acute cardiovascular disease (CVD) especially ST segment elevation myocardial infarction (STEMI), a leading cause of death worldwide, prompt diagnosis and treatment is of crucial importance to reduce both mortality and morbidity. During a pandemic such as coronavirus disease-2019 (COVID-19), it is critical to balance cardiovascular emergencies with infectious risk. In this work, we recommend using wearable device based mobile health (mHealth) as an early screening and real-time monitoring tool to address this balance and facilitate remote monitoring to tackle this unprecedented challenge. This recommendation may help to improve the efficiency and effectiveness of acute CVD patient management while reducing infection risk.
No takes yet. Share an insight, caveat, or question.
Ji et al. (2021) conducted a review in Acute cardiovascular disease (especially STEMI) during COVID-19. Wearable-based mobile health (mHealth) was evaluated. Wearable device-based mobile health (mHealth) is recommended as an early screening and real-time monitoring tool to manage acute cardiovascular disease patients during the COVID-19 pandemic.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: